Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OBI-902
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears IND for OBI-902 Phase 1/2 Trop-2 ADC Study by OBI Pharma
Details : OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology. It is being evaluated for advanced solid tumors.
Product Name : OBI-902
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 30, 2025
Lead Product(s) : OBI-902
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OBI Pharma Initiates Phase 1/2 Study for OBI-992, a TROP2-Targeted ADC
Details : OBI-992 is a novel antibody drug conjugate (ADC) cancer therapy targeting TROP2. It is being evaluated for the treatment of non-small cell lung cancer, small cell lung cancer & gastric cancer.
Product Name : OBI-992
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Biosion
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosion's Partner OBI Pharma Announces FDA Clearance for OBI-992 Phase 1/2 Study
Details : OBI-992 is a novel antibody drug conjugate (ADC) cancer therapy targeting TROP2. It is being evaluated for the treatment of non-small cell lung cancer, small cell lung cancer & gastric cancer.
Product Name : OBI-992
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Biosion
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OBI Pharma Announces FDA Clearance for Phase 1/2 Study of OBI-992
Details : OBI-992 is a TROP2-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor, evaluated for advanced solid tumors including lung and gastric cancers.
Product Name : OBI-992
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
March 01, 2024
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-3424,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OBI-3424 can induce immunogenic cell death and demonstrated impressive synergistic efficacy in combination with Pembrolizumab in various cancer models, Emerging science also demonstrated poor survival in gastric cancer patients who have high Globo H and ...
Product Name : OBI-3424
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2022
Lead Product(s) : OBI-3424,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-999
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OBI-999, uses Globo H antibody to recognize the cancer cells with high Globo H expression and releases the active drug to prevent tumor growth and kill tumor cells.
Product Name : OBI-999
Product Type : Antibody
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : OBI-999
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-888
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A first in class monoclonal antibody cancer immunotherapy, OBI-888 targets Globo H, antibody, a glycolipid antigen expressed in up to 15 epithelial cancers.
Product Name : OBI-888
Product Type : Antibody
Upfront Cash : Inapplicable
May 07, 2022
Lead Product(s) : OBI-888
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833
Details : In the trial, OBI-833 showed a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. The company’s novel first-in-class immuno-oncology portfolio against Globo H includes: Adagloxad Simolenin and OBI-833, a Globo H active im...
Product Name : OBI-833
Product Type : Vaccine
Upfront Cash : Inapplicable
November 19, 2020
Details : Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 antigens in different tumor types.
Product Name : OBI-3424
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2020
Lead Product(s) : OBI-999
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Second Orphan Drug Designation for OBI-999, Antibody-Drug Conjugate in combination with a validated payload (MMAE) & the antibody targeting Globo H, a glycolipid antigen found on multiple tumor types.
Product Name : OBI-999
Product Type : Antibody
Upfront Cash : Inapplicable
January 21, 2020
Lead Product(s) : OBI-999
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable